Anti-ceramide monoclonal antibody 2A2
We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
1. An anti-ceramide monoclonal antibody 2A2 IgM or a biologically active, antigen-binding fragment thereof deposited under international deposit number PTA-13418.
2. The 2A2 IgM of claim 1 wherein the 2A2 IgM antibody is humanized.
3. A pharmaceutical composition comprising the anti-ceramide monoclonal antibody 2A2 IgM or a biologically active, antigen-binding fragment thereof deposited under international deposit number PTA-13418.
4. The pharmaceutical composition of claim 3 wherein the antibody is humanized.
5. The pharmaceutical composition of claim 3 further comprising a statin.
6. The pharmaceutical composition of claim 3 further comprising imipramine.
7. A humanized IgG form of the 2A2 IgM antibody of claim 2 .
8. The pharmaceutical composition of claim 4 wherein the 2A2 IgM humanized antibody is a humanized IgG form.